Inhibition of Bone Metastasis from Breast Carcinoma by Rosmarinic Acid

Abstract

Skeletal disorders are a common complication of breast cancer and will be found in the vast majority of women with metastatic disease. Our study showed that rosmarinic acid (RA) could inhibit the migration of MDA‐MB-231BO human bone-homing breast cancer cells dose-dependently. Furthermore, in ST-2 murine bone marrow stromal cells cultured with RA there was a significant and dose-dependent increase in alkaline phosphatase (ALP) activity, with the number and size of mineralized nodules increasing. According to Western blot and quantitative real-time PCR assay, RA may inhibit bone metastasis from breast carcinoma mainly via the pathway of the receptor activator of NFκB ligand (RANKL)/RANK/osteoprotegerin (OPG) and by simultaneously suppressing the expression of interleukin-8 (IL-8). RA may thus be a good candidate for a new therapeutic approach in bone metastasis from breast carcinoma.

Key words

Prunella vulgaris L. - Lamiaceae - rosmarinic acid - bone metastasis - breast carcinoma

References

• 1 Jemal A, Siegel R, Ward E. Cancer statistics.  CA Cancer J Clin. 2007;  57 43-66
• 2 Lipton A, Demers L, Daniloff Y. Increased urinary excretion of pyridinium crosslinks in cancer patients.  Clin Chem. 1993;  39 614-618
• 3 Mundy G R. Metastasis to bone: causes, consequences and therapeutic opportunities.  Nat Rev Cancer. 2002;  2 584-593
• 4 Clines G A, Guise T A. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.  Endocr Relat Cancer. 2005;  12 549-583
• 5 Jemal A, Siegel R, Ward E. Cancer statistics.  CA Cancer J Clin. 2006;  56 106-130
• 6 Body J J. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.  Cancer. 2003;  97 859-865
• 7 Ma P L, Zhao P R, Tian A Q. The effect of Prunella vulgaris L. on Eca109 cells.  J Basic Clin Oncol. 2006;  19 199-200
• 8 Qiao S, Li W, Subouchi R. Rosmarinic acid inhibits the formation of reactive oxygen and nitrogen species in RAW264.7 macrophages.  Free Radic Res. 2005;  39 995-1003
• 9 Youn J, Lee K H, Won J. Beneficial effects of rosmarinic acid on suppression of collagen induced arthritis.  J Rheumatol. 2003;  30 1203-1207
• 10 Parnham M J, Kesselring K. Rosmarinic acid.  Drugs Future. 1985;  10 756-757
• 11 Wang Z J, Zhao Y Y, Wang F. Depsides from Prunella vulgaris.  Chin Chem Lett. 2000;  11 997-1001
• 12 Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion.  Physiol Rev. 2003;  83 337-376
• 13 Hale L V, Ma Y F, Santerre R F. Semi-quantitative fluorescence analysis of calcein binding as a measurement of in vitro mineralization.  Calcif Tissue Int. 2000;  67 80-84
• 14 Zhang J, Shen Y L, Liu J W. Antimetastatic effect of RA through inhibition of tumor invasion.  Biochem Pharmacol. 2005;  69 407-414
• 15 Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis.  Biochem Biophys Res Commun. 2005;  328 679-687
• 16 Hofbauer L C, Neubauer A, Heufelder A E. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.  Cancer. 2001;  92 460-470
• 17 Kong Y Y, Yoshida H, Sarosi I. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.  Nature. 1999;  397 315-323
• 18 Hsu H, Lacey D L, Dunstan C R. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.  Proc Natl Acad Sci USA. 1999;  96 3540-3545
• 19 Nakagawa N, Kinosaki M, Yamaguchi K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.  Biochem Biophys Res Commun. 1998;  253 395-400
• 20 Lacey D L, Timms E, Tan H L. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.  Cell. 1998;  93 165-176
• 21 Morony S, Capparelli C, Sarosi I. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.  Cancer Res. 2001;  61 4432-4436
• 22 Théoleyre S, Wittrant Y, Tat S K. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.  Cytokine Growth Factor Rev. 2004;  15 457-475
• 23 Lacey D L, Timms E, Tan H L. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.  Cell. 1998;  93 165-176
• 24 Simonet W S, Lacey D L, Dunstan C R. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.  Cell. 1997;  89 309-319
• 25 Williams G T, Smith C A, Spooncer E. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis.  Nature. 1990;  343 76-79
• 26 Guise T A, Yin J J, Taylor S D. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.  J Clin Invest. 1996;  98 1544-1549
• 27 Chirgwin J M, Guise T A. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.  Crit Rev Eukaryot Gene Expr. 2000;  10 159-178
• 28 Chirgwin J M, Mohammad K S, Guise T A. Tumor-bone cellular interactions in skeletal metastases.  J Musculoskelet Neuronal Interact. 2004;  4 308-318
• 29 Yoshimura T, Matsushima K, Tanaka S. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines.  Proc Natl Acad Sci USA. 1987;  84 9233-9237
• 30 Sozzani S, Locati M, Allavena P. Chemokines: a superfamily of chemotactic cytokines.  Int J Clin Lab Res. 1996;  26 69-82
• 31 Bendre M S, Gaddy-Kurten D, Mon-Foote T. Expression of interleukin-8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo.  Cancer Res. 2002;  62 5571-5579
• 32 Bendre M S, Margulies A G, Walser B. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway.  Cancer Res. 2005;  65 11001-11009
• 33 Benoy I H, Salgado R, Van Dam P. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival.  Clin Cancer Res. 2004;  10 7157-7162
• 34 Bendre M S, Montague D C, Peery T. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.  Bone. 2003;  33 28-37
• 35 Thudi N K, Martin C K, Nadella M V. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.  Prostate. 2008;  68 1116-1125